Matt Devalaraja

Co-CSO, Head-Research & Development at Corvidia Therapeutics, Inc.

Matt Devalaraja

Matt Devalaraja

Co-CSO, Head-Research & Development at Corvidia Therapeutics, Inc.

Overview

RelSci Relationships

4355

Relationships

View Relationship Details

RelSci Relationships are individuals Matt Devalaraja likely has professional access to. A relationship does not necessarily indicate a personal connection.

Susan Silbermann

President & General Manager at Pfizer Vaccines LLC

Relationship likelihood: Strong

Rahul Kakkar

Chief Executive Officer at Pandion Therapeutics, Inc.

Relationship likelihood: Strong

Albert Bourla

Chairman of the Board & Chief Executive Officer at Pfizer, Inc.

Relationship likelihood: Strong

Tara J. Gabbai

Assistant General Counsel & Assistant Secretary in the Corporate Governance Group, Legal Division at Pfizer, Inc.

Relationship likelihood: Strong

Mikael Dolsten

Chief Scientific Officer & President, Worldwide Research, Development & Medical at Pfizer, Inc.

Relationship likelihood: Strong

Sally Susman

Chief Corporate Affairs Officer & Executive Vice President at Pfizer, Inc.

Relationship likelihood: Strong

Michael Anthony White

Chief Scientific Officer at Samumed LLC

Relationship likelihood: Strong

William Gregory

Senior Director, Worldwide Safety & Regulatory at Pfizer, Inc.

Relationship likelihood: Strong

Doug Giordano

President, Treasurer & Director at Array BioPharma Inc.

Relationship likelihood: Strong

John C. Mesloh

Director & Treasurer at Atlantic District - Lutheran Church Missouri Synod

Relationship likelihood: Strong

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.

In The News

PR Newswire

January 29, 2020

Corvidia Therapeutics Announces Publication in Science Translational Medicine of Strategy for Lowering Triglycerides Using a Mimetic Peptide; - Early preclinical studies show peptide D6PV has the ability to activate the enzyme called Lipo-Protein Lipase (

ENP Newswire

April 30, 2018

-Corvidia Therapeutics Secures $ 60 Million in Series B Funding to Accelerate Clinical Work

Business Wire

April 25, 2018

Corvidia Therapeutics Secures $60 Million in Series B Funding to Accelerate Clinical Work

PR Newswire

February 17, 2016

Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners

Paths to Matt Devalaraja

Potential Connections via
Relationship Science

You

Matt Devalaraja

Co-CSO, Head-Research & Development at Corvidia Therapeutics, Inc.

Education

PhD Unknown

University of Kentucky

The University of Kentucky is a public, land grant university dedicated to improving people's lives through excellence in education, research and creative work, service, and health care. As Kentucky's flagship institution, the University plays a critical leadership role by promoting diversity, inclusion, economic development, and human well-being. The University of Kentucky is guided by its core values: Integrity, Excellence, Mutual respect and human dignity, Diversity and inclusion, Academic freedom, Personal and institutional responsibility and accountability, Shared governance, A sense of community, Work-life sensitivity, Civic engagement and Social responsibility.

Career History

Co-CSO, Head-Research & Development

2015 - Current

Corvidia Therapeutics, Inc.

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

Head of Biologics Discovery, Ann Arbor

Tenure Unconfirmed

Pfizer, Inc.

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Head of Immunology Research, Pharmacokinetics & Toxicology Groups

Tenure Unconfirmed

Human Genome Sciences, Inc.

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Investments

Details Hidden

Corvidia Therapeutics, Inc.

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

Other Affiliations

Matt Devalaraja is affiliated with Corvidia Therapeutics, Inc., Pfizer, Inc., Human Genome Sciences, Inc., AstraZeneca Plc

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Matt Devalaraja. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Matt Devalaraja's profile does not indicate a business or promotional relationship of any kind between RelSci and Matt Devalaraja.